| Identification | Back Directory | [Name]
KX-02 KX-2-361 KX-2361 | [CAS]
897016-26-1 | [Synonyms]
KX-02)
KX2-361
(KX-2361
KX-02 KX-2-361 KX-2361
KX2361,KX2 361,KX-2-361
2-Pyridineacetamide, N-[(3-fluorophenyl)methyl]-5-[4-(4-morpholinyl)phenyl]- | [Molecular Formula]
C24H24FN3O2 | [MDL Number]
MFCD28502133 | [MOL File]
897016-26-1.mol | [Molecular Weight]
405.46 |
| Hazard Information | Back Directory | [Uses]
KX2-361 (KX-02) is a Src-kinase and tubulin polymerization inhibitor. KX2-361 shows good oral bioavailability and readily crosses the BBB in mice. KX2-361 shows anti-tumor activity and induces apoptosis of Glioblastoma (GBM) cell[1]. | [in vivo]
KX2?361 significantly delays progression of orthotopic GL261 brain tumors and produces long?term survival[1].
KX2-361 demonstrates appreciable brain penetration when dosed orally to mice (20 mg/kg), with a brain Cmax of 4025±319 ng/g observed 15 min post-dosing and an overall exposure (AUClast) of 5044±355 h ng/g[1].
| [References]
[1] Ciesielski MJ, et al. KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma. J Neurooncol. 2018 Dec;140(3):519-527. DOI:10.1007/s11060-018-2992-4 |
|
|